Bladder cancer chemotherapy neoadjuvant therapy

*Adaptation Psychological Humans Quality of Life Survivors/*psychology Urinary Bladder Neoplasms/mortality/pathology/*psychology Bladder cancer Cystectomy Diagnosis Patients’ experience Treatment FUNDING: This work was funded by Yorkshire Cancer Research (grant number S388).

Adjuvants Immunologic/*administration & dosage/adverse effects Administration Intravesical Antineoplastic Agents/*administration & dosage/adverse effects BCG Vaccine Carcinoma in Situ/mortality/pathology/*therapy Combined Modality Therapy/adverse effects/methods Disease Progression Drug Administration Schedule Humans Interferon-alpha/*administration & dosage/adverse effects Neoplasm Recurrence Local Randomized Controlled Trials as Topic Time Factors Urinary Bladder Neoplasms/mortality/pathology/*therapy Withholding Treatment/statistics & numerical data

Administration Intravesical BCG Vaccine/administration & dosage/*therapeutic use Chemotherapy Adjuvant Dose-Response Relationship Drug Drug Administration Schedule Humans Neoplasm Recurrence Local Prospective Studies Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/mortality/surgery

Aged Blood Loss Surgical Cystectomy/*adverse effects/*methods Female Humans Length of Stay Male Middle Aged Operative Time Postoperative Complications/etiology Quality of Life Randomized Controlled Trials as Topic Robotic Surgical Procedures/*adverse effects/*methods Treatment Outcome Urinary Bladder/*surgery Urinary Bladder Neoplasms/surgery Urinary Diversion/*adverse effects/*methods

Administration Intravesical Antineoplastic Agents/administration & dosage/*therapeutic use BCG Vaccine/administration & dosage/*therapeutic use Humans Treatment Outcome Urinary Bladder Neoplasms/*drug therapy